Edwards Lifesciences Corporation (EW), a global leader in patient-focused medical innovations, was founded in 1958 and is headquartered in Irvine, California. With a market cap of $42.2 billion, Edwards Lifesciences is a key player in the healthcare industry, specializing in cutting-edge technologies for structural heart disease and critical care monitoring.
Companies with a market value of $10 billion or more are classified as “large-cap stocks,” Edwards Lifesciences firmly belongs in this category. With a strong track record of financial performance and a commitment to advancing medical technology, Edwards excels in specialized healthcare sectors, including structural heart innovations and critical care solutions. Its innovative products and patient-focused approach drive significant impact across global healthcare markets.
Edwards Lifesciences is currently trading 25.6% below its 52-week high of $96.12, reached on Mar. 28. Shares of Edwards Lifesciences gained 7.1% over the three months, underperforming the broader S&P 500 Index ($SPX) 12.6% gains during the same time frame.
Over the longer term, EW has posted a YTD loss of 6.2%, falling short of SPX’s 27.7% return. Similarly, over the past 52 weeks, EW reported a 2.9% gain, underperforming SPX’s impressive 33.9% growth during the same period.
To confirm the recent bearish trend, EW has consistently traded below its 200-day moving average since late July. However, it has stayed above its 50-day moving average since mid-November.
On Oct. 24, Edwards Lifesciences posted its Q3 results, with shares closing slightly lower despite solid performance. The company reported an adjusted EPS of $0.67, aligning with consensus estimates and reflecting a strong 21.8% year-over-year growth. Revenue came in at $1.35 billion, marking an 8.9% increase compared to the prior year. Edwards reaffirmed its full-year sales growth outlook of 8% to 10% and maintained guidance across its three key product segments. For Q4, the company anticipates revenue in the range of $1.33 billion to $1.39 billion, with projected EPS between $0.53 and $0.57.
Edwards Lifesciences has lagged behind its competitor, Medtronic plc (MDT). MDT stock has edged up 2% on a YTD basis and returned 6.3% over the past 52 weeks.
Despite EW underperforming the broader sector, analysts maintain a moderately bullish outlook on the stock. Of the 27 analysts covering it, the consensus rating is “Moderate Buy,” with a mean price target of $76.46, indicating a potential upside of 6.9% from its current level.
On the date of publication, Rashmi Kumari did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
